Bioject Announces National Institutes of Health Begins Human Ebola Vaccine Trial Utilizing Biojector 2000

BEDMINSTER, N.J. -- Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, announced today that the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, recently began its first human trial of a vaccine to prevent Ebola infection utilizing the Biojector 2000 (B-2000). The B-2000 is a needle-free injection system that is powered by a compressed gas system and is the only device being utilized in the study.

Earlier this year, Bioject had entered into a services and supply subcontract with SAIC-Frederick, Inc., a subsidiary of Science Applications International Corporation-Frederick (SAIC-Frederick) under its contract with the National Cancer Institute, Frederick, where by Bioject will supply the VRC/NIAID, with the non-exclusive right to utilize Bioject's B-2000 needle- free injection systems in VRC-sponsored clinical trials for experimental vaccines against HIV and Ebola. The HIV human clinical trials are currently underway.

Bioject Medical Technologies Inc., is an innovative developer and manufacturer of needle-free drug delivery systems and vial adapter products. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.

Source: Bioject Medical Technologies Inc.